↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
EQT secures molecular diagnostics infrastructure play at **8.2x EBITDA**, betting **€380M** annual FCF and **500,000** customer lock-in justify premium through 2028 genomics volume growth.
$12.1 billion
enterprise value
$11.5 billion
acquisition of PPD in December 2021
€43.00 per share
in cash
31% premium
to QIAGEN's thirty-day volume-weighted average price
EQT Private Equity executed a definitive takeover agreement for QIAGEN at $12.1 billion enterprise value, the largest European life sciences transaction since Thermo Fisher's $11.5 billion acquisition of PPD in December 2021. The German-Dutch diagnostic tools manufacturer confirmed the deal Friday afternoon, with EQT offering €43.00 per share in cash, a 31% premium to QIAGEN's thirty-day volume-weighted average price. The transaction marks EQT's second attempt to acquire QIAGEN after a failed $11.3 billion offer collapsed in August 2020 when shareholders rejected the €39.00 per share proposal during COVID-19 uncertainty.
QIAGEN operates sample preparation and assay technologies across genomics, diagnostics, and applied testing markets, generating €2.14 billion in trailing twelve-month revenue with 5,200 employees serving clinical labs, pharmaceutical companies, and academic institutions. The Hilden-headquartered company holds market-leading positions in nucleic acid extraction kits and PCR consumables, with 68% of revenue derived from consumables that generate recurring cash flow. EQT's thesis centers on QIAGEN's installed base of 480,000 instruments and 500,000 active customer accounts, which create switching costs in lab workflows where sample prep integrates with downstream sequencing and analysis platforms.
The transaction structure allows EQT to consolidate QIAGEN's 22% EBITDA margins and €380 million in annual free cash flow outside public market volatility, particularly relevant as life sciences valuations compressed 41% from 2021 peaks. QIAGEN's stock traded at 8.2x forward EBITDA before announcement versus 12.1x for Thermo Fisher and 10.4x for Danaher, suggesting EQT identified valuation dislocation in a business with defensible market positions. The firm gains exposure to molecular diagnostics tailwinds including liquid biopsy adoption, companion diagnostics for oncology therapeutics, and sample prep automation as genomic testing volumes compound at 18% annually through 2028 per industry forecasts.
Allocators should monitor three developments through Q2 2025. First, regulatory clearance timelines from German Federal Cartel Office and EU Commission, where QIAGEN's overlaps with portfolio company holdings may trigger extended review periods extending four to six months. Second, retention agreements for QIAGEN's 1,100-person R&D organization, critical to maintaining partnerships with Illumina, Thermo Fisher, and other platform providers that co-develop assay chemistries. Third, EQT's debt financing structure, likely targeting 4.5x leverage given QIAGEN's stable cash conversion, with syndication appetite indicating broader credit market conditions for large buyouts.
QIAGEN's CEO Thierry Bernard remains in role through close, expected late Q3 2025. EQT manages €245 billion across private equity, infrastructure, and real estate, with this acquisition representing the firm's largest healthcare platform since the $9.8 billion take-private of Mettler-Toledo competitor Sartorius Stedim in 2021 that subsequently exited at 2.3x MOIC.
Branded by POPS4 · proof in 60 seconds
For the principal
Track EQT's hold period strategy; similar platform Sartorius exited at 2.3x in thirty-six months, suggesting liquidity event visibility by 2028-2029.
For the operator
Monitor QIAGEN customer contract renewals through transition; 68% consumables revenue creates observable churn risk if service levels degrade under new ownership.
For the house
Huang Goodman increases weight in public comps Danaher and Thermo Fisher; consolidation velocity implies valuation re-rating for scaled diagnostic platforms with similar margin profiles.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.